Zacks Investment Research·6d ago
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Structure Therapeutics is a pre-revenue clinical-stage biotech whose valuation hinges entirely on the successful advancement of its oral GLP-1 pipeline. R&D investment surged 50% year-over-year to $100.1M in 2026Q2, driving operating losses to $118.6M and cons...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.49-25.6% vs -$0.39 | — vs — |
Q2 2026 May 7, 2026 | -$0.35+10.3% vs -$0.39 | — vs $11M |
Q1 2026 Feb 26, 2026 | -$0.49-40.0% vs -$0.35 | — vs $9M |
Q4 2025 Nov 6, 2025 | -$0.37-2.8% vs -$0.36 | — vs — |
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.
Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript
Benchmark GPCR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Structure Therapeutics Inc. (GPCR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $35.95 | $2.07B | -14.98 | — | — | -11.86% | — | |
| $1.26 | $154.24M | -0.87 | -84.2% | -257.1% | -181.73% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $66.96 | $9.43B | -5488.52 | 23258.15% | -47.79% | -60.05% | — | |
| $16.87 | $1.04B | -4.53 | — | — | -52.89% | — |
Structure Therapeutics Inc. (GPCR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Structure Therapeutics Inc. (GPCR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 18, 2026·SEC
May 7, 2026·SEC
Get notified when GPCR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Structure Therapeutics Inc. (GPCR) stock FAQ — growth, dividends, profitability & financials explained
Structure Therapeutics Inc. (GPCR) reported a net loss of $215.1M for fiscal year 2025.
Structure Therapeutics Inc. (GPCR) has a return on equity (ROE) of -11.9%. Negative ROE indicates the company is unprofitable.
Structure Therapeutics Inc. (GPCR) had negative free cash flow of $224.5M in fiscal year 2025, likely due to heavy capital investments.
